Genzyme and Isis enter major CV collaboration
Genzyme and antisense drug developer Isis have agreed to partner for the development of Isis' mipomersen (formerly ISIS 301012), a Phase III injectable that lowers lipid levels in patients with familial hypercholesterolemia (FH).
- Antisense, Oligonucleotides
- Large Molecule
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.